Boston Scientific Corporation (BSX) announced on Monday that it has entered into an agreement to acquire Cortex, Inc., a company specializing in medical technology. The specifics of the financial arrangement for the acquisition have not been made public.
Cortex is known for its OptiMap system, a diagnostic mapping solution that aids physicians in identifying triggers outside the pulmonary veins, which are crucial in the treatment of atrial fibrillation (AF), a type of heart rhythm disorder.
Nick Spadea-Anello, the Global President of Electrophysiology at Boston Scientific, stated, "We believe that integrating Cortex's technology will enhance our electrophysiology portfolio by providing a unique cardiac mapping solution to tackle complex AF cases."
The transaction is anticipated to be finalized in the first half of 2025.
